miRNA Stability in Frozen Plasma Samples

Balzano, Francesca; Deiana, Marta; Giudici, Silvia Dei; Oggiano, Annalisa; Baralla, Angela; Pasella, Sara; Mannu, Andrea; Pescatori, Mario; B, Porcu; Fanciulli, Giuseppe; Zinellu, Angelo; Carru, Ciriaco; Deiana, Luca

doi:10.3390/molecules201019030

Cited by 88 publications

(64 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because of plasma miRNAs' high stability under handling and storage conditions [17], they have the potential to become novel diagnostic biomarkers for cancer [18,19], respiratory diseases [20], and other conditions. Nonsyndromic cleft lip is one type of oral clefting without cleft palate or other developmental syndromes.…”

Section: Discussionmentioning

confidence: 99%

Expression profile of plasma microRNAs in nonsyndromic cleft lip and their clinical significance as biomarkers

Zou

et al. 2016

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Expression profile of plasma microRNAs in nonsyndromic cleft lip and their clinical significance as biomarkers

Zou

et al. 2016

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

“…One benefit of extracellular miRNAs as CVD biomarkers is that they can be sampled non-invasively and are present in all biological fluids (Boon & Vickers, 2013). miRNA biomarker studies also benefit from the high stability and relatively long half-life of miRNAs in samples, the required low input for detection, the high specificity of currently available probes, and the increasing available detection strategies and technologies (Balzano, et al, 2015; Creemers, Tijsen, & Pinto, 2012). Aside from diagnostic potential and monitoring response to drug treatments, miRNA-based therapy is a rapidly emerging market that is proving to be very lucrative to the pharmaceutical industry -- expected to reach 1 billion in 2019 (www.bccresearch.com).…”

Section: Current Development Of Mirna Therapeutics That May Impactmentioning

confidence: 99%

HDL and microRNA therapeutics in cardiovascular disease

Michell

Vickers

2016

Pharmacology & Therapeutics

View full text Add to dashboard Cite

microRNAs (miRNA) are small non-coding RNAs (sRNA) that post-transcriptionally regulate gene (mRNA) expression and are implicated in many biological processes and diseases. Many miRNAs have been reported to be altered in cardiovascular disease (CVD); both cellular and extracellular miRNA levels are affected by hypercholesterolemia and atherosclerosis. We and other groups have reported that lipoproteins transport miRNAs in circulation and these lipoprotein signatures are significantly altered in hypercholesterolemia and coronary artery disease (CAD). Extracellular miRNAs are a new class of potential biomarkers for CVD; however, they may also be new drug targets as high-density lipoproteins (HDL) transfer functional miRNAs to recipient cells in an endocrine-like form of intercellular communication that likely suppresses vascular inflammation. Recently, RNA-based drugs have emerged as the next frontier in drug therapy, and there are many miRNA inhibitors and mimics in clinical development. Here, we discuss specific miRNA drug targets and how their manipulation may impact CVD. We also address the potential for manipulating HDL-miRNA levels to treat CVD and the use of HDL as a delivery vehicle for RNA and chemical drugs. Finally, we outline the current and future challenges for HDL and miRNA-based therapeutics for the prevention and treatment of CVD.

show abstract

“…Previous reports have shown that miRNAs participate in some cell signaling processes, including apoptosis, cell proliferation, and epithelial-to-mesenchymal transition [19, 20]. Quantification of miRNA expression can be performed even using relatively degraded samples, such as FFPE samples, in a PCR-based test (real-time PCR) [14, 21-23]. In this study, we used FFPE samples as well as snap-frozen samples (different quality of RNA) and examined the expression of several candidate miRNAs.…”

Section: Discussionmentioning

confidence: 99%

Molecular Nodal Staging Using miRNA Expression in Lung Cancer Patients by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration

et al. 2018

View full text Add to dashboard Cite

Background: The limited negative predictive value of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has often been discussed. Objective: The aim of this study was to identify a highly sensitive molecular biomarker for lymph node staging by EBUS-TBNA. Methods: Five microRNAs (miRNAs) (miR-200a, miR-200b, miR-200c, miR-141, and let-7e) were selected as biomarker candidates for the detection of nodal metastasis in a miRNA expression analysis. After having established a cutoff level of expression for each marker to differentiate malignant from benign lymph nodes among surgically dissected lymph nodes, the cutoff level was applied to snap-frozen EBUS-TBNA samples. Archived formalin-fixed paraffin- embedded (FFPE) samples rebiopsied by EBUS-TBNA after induction chemoradiotherapy were also analyzed. Results: The expression of all candidate miRNAs was significantly higher in metastatic lymph nodes than in benign ones (p < 0.05) among the surgical samples. miR-200c showed the highest diagnostic yield, with a sensitivity of 95.4% and a specificity of 100%. When the cutoff value for miR-200c was applied to the snap-frozen EBUS-TBNA samples, the sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy were 97.4, 81.8, 95.0, 90.0, and 94.0%, respectively. For restaging FFPE EBUS- TBNA samples, the sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy were 100, 60.0, 80.0, 100, and 84.6%, respectively. Among the restaged samples, 4 malignant lymph nodes were false negative by EBUS-TBNA, but they were accurately identified by miR-200c. Conclusions: miR-200c can be used as a highly sensitive molecular staging biomarker that will enhance nodal staging of lung cancer.

show abstract

miRNA Stability in Frozen Plasma Samples

Cited by 88 publications

References 25 publications

Expression profile of plasma microRNAs in nonsyndromic cleft lip and their clinical significance as biomarkers

Expression profile of plasma microRNAs in nonsyndromic cleft lip and their clinical significance as biomarkers

HDL and microRNA therapeutics in cardiovascular disease

Molecular Nodal Staging Using miRNA Expression in Lung Cancer Patients by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration

Contact Info

Product

Resources

About